The dose expansion part enrolled pts with EGFRm NSCLC with prior EGFR TKI and platinum-based chemotherapy. The dose escalation part was presented previously. We report safety and activity in such pts treated in a phase I study (NCT03260491) with patritumab deruxtecan, a HER3 directed antibody drug conjugate, at the 5.6 mg/kg recommended dose for expansion. There are few treatment options for pts with advanced EGFRm NSCLC after failure of EGFR TKI and platinum-based chemotherapy.
0 Comments
Leave a Reply. |